Free Trial
TSE:PMN

ProMIS Neurosciences (PMN) Stock Price, News & Analysis

ProMIS Neurosciences logo

About ProMIS Neurosciences Stock (TSE:PMN)

Key Stats

Today's Range
N/A
50-Day Range
C$6.00
C$6.00
52-Week Range
N/A
Volume
19,701 shs
Average Volume
3,327 shs
Market Capitalization
C$51.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

PMN Stock News Headlines

ProMIS Neurosciences reports Q3 EPS 31c vs (19c) last year
Breaking News: Tesla headed to $500…
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
See More Headlines

PMN Stock Analysis - Frequently Asked Questions

Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Keurig Dr Pepper (KDP), Biocept (BIOC), Onconova Therapeutics (ONTX), Spectra7 Microsystems (SEV) and TherapeuticsMD (TXMD).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
C$-20,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$7,558.00
Book Value
C($0.72) per share

Miscellaneous

Free Float
N/A
Market Cap
C$51.48 million
Optionable
Not Optionable
Beta
1.19
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (TSE:PMN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners